APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sexual Dysfunction Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sexual Dysfunction Drugs Market Outlook and Growth Opportunities 2026

20 December 2025192 pages

Choose your research edition.

Industry ResearchSexual Dysfunction Drugs Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Sexual Dysfunction Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Sexual Dysfunction Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sexual Dysfunction Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Sexual Dysfunction Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Sexual Dysfunction Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sexual Dysfunction Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sexual Dysfunction Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sexual Dysfunction Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sexual Dysfunction Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sexual Dysfunction Drugs market include Takeda, Teva Pharmaceutical Industries, Merck, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer, AbbVie and Vietstar Biomedical Research, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Sexual Dysfunction Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sexual Dysfunction Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sexual Dysfunction Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sexual Dysfunction Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Sexual Dysfunction Drugs Segment by Company

Takeda

Teva Pharmaceutical Industries

Merck

Eli Lilly

Pfizer

GlaxoSmithKline

Bayer

AbbVie

Vietstar Biomedical Research

S1 Biopharma

NexMed

Leadiant Biosciences

Ivix LLX

Emotional Brain

Apricus Biosciences

Sexual Dysfunction Drugs Segment by Type

Hormonal Therapy

Transurethral Therapy

Oral Therapy

Intracavernosal Therapy

Sexual Dysfunction Drugs Segment by Application

Male

Female

Sexual Dysfunction Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Sexual Dysfunction Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Sexual Dysfunction Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sexual Dysfunction Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Sexual Dysfunction Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sexual Dysfunction Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sexual Dysfunction Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sexual Dysfunction Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Sexual Dysfunction Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sexual Dysfunction Drugs industry.

Chapter 3: Detailed analysis of Sexual Dysfunction Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Sexual Dysfunction Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Sexual Dysfunction Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sexual Dysfunction Drugs Industry Trends Table 2. Sexual Dysfunction Drugs Industry Drivers Table 3. Sexual Dysfunction Drugs Industry Opportunities and Challenges Table 4. Sexual Dysfunction Drugs Industry Restraints Table 5. Global Sexual Dysfunction Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sexual Dysfunction Drugs Revenue Share by Company (2021-2026) Table 7. Global Sexual Dysfunction Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Sexual Dysfunction Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Sexual Dysfunction Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Sexual Dysfunction Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Sexual Dysfunction Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Sexual Dysfunction Drugs Company, Product Type & Application Table 13. Global Sexual Dysfunction Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Sexual Dysfunction Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hormonal Therapy Table 18. Significant Companies of Transurethral Therapy Table 19. Significant Companies of Oral Therapy Table 20. Significant Companies of Intracavernosal Therapy Table 21. Global Sexual Dysfunction Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Sexual Dysfunction Drugs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Sexual Dysfunction Drugs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Sexual Dysfunction Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Sexual Dysfunction Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Sexual Dysfunction Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Sexual Dysfunction Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Sexual Dysfunction Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Sexual Dysfunction Drugs Sales Value Share by Type (2021-2026) Table 30. Global Sexual Dysfunction Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Male Table 32. Significant Companies of Female Table 33. Global Sexual Dysfunction Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Sexual Dysfunction Drugs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Sexual Dysfunction Drugs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Sexual Dysfunction Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Sexual Dysfunction Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Sexual Dysfunction Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Sexual Dysfunction Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Sexual Dysfunction Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Sexual Dysfunction Drugs Sales Value Share by Application (2021-2026) Table 42. Global Sexual Dysfunction Drugs Sales Value Share by Application (2027-2032) Table 43. Global Sexual Dysfunction Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Sexual Dysfunction Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Sexual Dysfunction Drugs Sales Market Share by Region (2021-2026) Table 46. Global Sexual Dysfunction Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Sexual Dysfunction Drugs Sales Market Share by Region (2027-2032) Table 48. Global Sexual Dysfunction Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Sexual Dysfunction Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Sexual Dysfunction Drugs Sales Value Share by Region (2021-2026) Table 51. Global Sexual Dysfunction Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Sexual Dysfunction Drugs Sales Value Share by Region (2027-2032) Table 53. Global Sexual Dysfunction Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Sexual Dysfunction Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Sexual Dysfunction Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Sexual Dysfunction Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Sexual Dysfunction Drugs Sales by Country (2021-2026) & (K Units) Table 58. Global Sexual Dysfunction Drugs Sales Market Share by Country (2021-2026) Table 59. Global Sexual Dysfunction Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Sexual Dysfunction Drugs Sales Market Share by Country (2027-2032) Table 61. Global Sexual Dysfunction Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Sexual Dysfunction Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Sexual Dysfunction Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Sexual Dysfunction Drugs Sales Value Market Share by Country (2027-2032) Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Takeda Sexual Dysfunction Drugs Product Portfolio Table 69. Takeda Recent Development Table 70. Teva Pharmaceutical Industries Company Information Table 71. Teva Pharmaceutical Industries Business Overview Table 72. Teva Pharmaceutical Industries Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Teva Pharmaceutical Industries Sexual Dysfunction Drugs Product Portfolio Table 74. Teva Pharmaceutical Industries Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck Sexual Dysfunction Drugs Product Portfolio Table 79. Merck Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Eli Lilly Sexual Dysfunction Drugs Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pfizer Sexual Dysfunction Drugs Product Portfolio Table 89. Pfizer Recent Development Table 90. GlaxoSmithKline Company Information Table 91. GlaxoSmithKline Business Overview Table 92. GlaxoSmithKline Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline Sexual Dysfunction Drugs Product Portfolio Table 94. GlaxoSmithKline Recent Development Table 95. Bayer Company Information Table 96. Bayer Business Overview Table 97. Bayer Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Bayer Sexual Dysfunction Drugs Product Portfolio Table 99. Bayer Recent Development Table 100. AbbVie Company Information Table 101. AbbVie Business Overview Table 102. AbbVie Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. AbbVie Sexual Dysfunction Drugs Product Portfolio Table 104. AbbVie Recent Development Table 105. Vietstar Biomedical Research Company Information Table 106. Vietstar Biomedical Research Business Overview Table 107. Vietstar Biomedical Research Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Vietstar Biomedical Research Sexual Dysfunction Drugs Product Portfolio Table 109. Vietstar Biomedical Research Recent Development Table 110. S1 Biopharma Company Information Table 111. S1 Biopharma Business Overview Table 112. S1 Biopharma Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. S1 Biopharma Sexual Dysfunction Drugs Product Portfolio Table 114. S1 Biopharma Recent Development Table 115. NexMed Company Information Table 116. NexMed Business Overview Table 117. NexMed Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. NexMed Sexual Dysfunction Drugs Product Portfolio Table 119. NexMed Recent Development Table 120. Leadiant Biosciences Company Information Table 121. Leadiant Biosciences Business Overview Table 122. Leadiant Biosciences Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Leadiant Biosciences Sexual Dysfunction Drugs Product Portfolio Table 124. Leadiant Biosciences Recent Development Table 125. Ivix LLX Company Information Table 126. Ivix LLX Business Overview Table 127. Ivix LLX Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Ivix LLX Sexual Dysfunction Drugs Product Portfolio Table 129. Ivix LLX Recent Development Table 130. Emotional Brain Company Information Table 131. Emotional Brain Business Overview Table 132. Emotional Brain Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Emotional Brain Sexual Dysfunction Drugs Product Portfolio Table 134. Emotional Brain Recent Development Table 135. Apricus Biosciences Company Information Table 136. Apricus Biosciences Business Overview Table 137. Apricus Biosciences Sexual Dysfunction Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Apricus Biosciences Sexual Dysfunction Drugs Product Portfolio Table 139. Apricus Biosciences Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Sexual Dysfunction Drugs Distributors List Table 143. Sexual Dysfunction Drugs Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Sexual Dysfunction Drugs Product Image Figure 2. Global Sexual Dysfunction Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sexual Dysfunction Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Sexual Dysfunction Drugs Sales (2021-2032) & (K Units) Figure 5. Global Sexual Dysfunction Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Sexual Dysfunction Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hormonal Therapy Image Figure 10. Transurethral Therapy Image Figure 11. Oral Therapy Image Figure 12. Intracavernosal Therapy Image Figure 13. Global Sexual Dysfunction Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Sexual Dysfunction Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Sexual Dysfunction Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Sexual Dysfunction Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Sexual Dysfunction Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Sexual Dysfunction Drugs Sales Value Share by Type (2021-2032) Figure 19. Male Image Figure 20. Female Image Figure 21. Global Sexual Dysfunction Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Sexual Dysfunction Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Sexual Dysfunction Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Sexual Dysfunction Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Sexual Dysfunction Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Sexual Dysfunction Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Sexual Dysfunction Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Sexual Dysfunction Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Sexual Dysfunction Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Sexual Dysfunction Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Sexual Dysfunction Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Sexual Dysfunction Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Sexual Dysfunction Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Sexual Dysfunction Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Sexual Dysfunction Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Sexual Dysfunction Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Sexual Dysfunction Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Sexual Dysfunction Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Sexual Dysfunction Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Sexual Dysfunction Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Sexual Dysfunction Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Sexual Dysfunction Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Hormonal Therapy
  • Transurethral Therapy
  • Oral Therapy
  • Intracavernosal Therapy
Applications
  • Male
  • Female
Companies covered
  • Takeda
  • Teva Pharmaceutical Industries
  • Merck
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AbbVie
  • Vietstar Biomedical Research
  • S1 Biopharma
  • NexMed
  • Leadiant Biosciences
  • Ivix LLX
  • Emotional Brain
  • Apricus Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Sexual Dysfunction Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Sexual Dysfunction Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Sexual Dysfunction Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Sexual Dysfunction Drugs Market Dynamics
  1. 2.1 Sexual Dysfunction Drugs Industry Trends
  2. 2.2 Sexual Dysfunction Drugs Industry Drivers
  3. 2.3 Sexual Dysfunction Drugs Industry Opportunities and Challenges
  4. 2.4 Sexual Dysfunction Drugs Industry Restraints
3 Sexual Dysfunction Drugs Market by Company
  1. 3.1 Global Sexual Dysfunction Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Sexual Dysfunction Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Sexual Dysfunction Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Sexual Dysfunction Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Sexual Dysfunction Drugs Company Ranking (2024-2026)
  6. 3.6 Global Sexual Dysfunction Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Sexual Dysfunction Drugs Company Product Type and Application
  8. 3.8 Global Sexual Dysfunction Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Sexual Dysfunction Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Sexual Dysfunction Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Sexual Dysfunction Drugs Market by Type
  1. 4.1 Sexual Dysfunction Drugs Type Introduction
  2. 4.1.1 Hormonal Therapy
  3. 4.1.2 Transurethral Therapy
  4. 4.1.3 Oral Therapy
  5. 4.1.4 Intracavernosal Therapy
  6. 4.2 Global Sexual Dysfunction Drugs Sales Volume by Type
  7. 4.2.1 Global Sexual Dysfunction Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Sexual Dysfunction Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Sexual Dysfunction Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Sexual Dysfunction Drugs Sales Value by Type
  11. 4.3.1 Global Sexual Dysfunction Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Sexual Dysfunction Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Sexual Dysfunction Drugs Sales Value Share by Type (2021-2032)
5 Sexual Dysfunction Drugs Market by Application
  1. 5.1 Sexual Dysfunction Drugs Application Introduction
  2. 5.1.1 Male
  3. 5.1.2 Female
  4. 5.2 Global Sexual Dysfunction Drugs Sales Volume by Application
  5. 5.2.1 Global Sexual Dysfunction Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Sexual Dysfunction Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Sexual Dysfunction Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Sexual Dysfunction Drugs Sales Value by Application
  9. 5.3.1 Global Sexual Dysfunction Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Sexual Dysfunction Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Sexual Dysfunction Drugs Sales Value Share by Application (2021-2032)
6 Sexual Dysfunction Drugs Regional Sales and Value Analysis
  1. 6.1 Global Sexual Dysfunction Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sexual Dysfunction Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Sexual Dysfunction Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Sexual Dysfunction Drugs Sales by Region (2027-2032)
  5. 6.3 Global Sexual Dysfunction Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Sexual Dysfunction Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Sexual Dysfunction Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Sexual Dysfunction Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Sexual Dysfunction Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Sexual Dysfunction Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Sexual Dysfunction Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Sexual Dysfunction Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Sexual Dysfunction Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Sexual Dysfunction Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Sexual Dysfunction Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Sexual Dysfunction Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Sexual Dysfunction Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Sexual Dysfunction Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Sexual Dysfunction Drugs Sales Value Share by Country, 2025 VS 2032
7 Sexual Dysfunction Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Sexual Dysfunction Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sexual Dysfunction Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Sexual Dysfunction Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Sexual Dysfunction Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Sexual Dysfunction Drugs Sales by Country (2027-2032)
  6. 7.4 Global Sexual Dysfunction Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Sexual Dysfunction Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Sexual Dysfunction Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Sexual Dysfunction Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Sexual Dysfunction Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Sexual Dysfunction Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Sexual Dysfunction Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva Pharmaceutical Industries
  8. 8.2.1 Teva Pharmaceutical Industries Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Sexual Dysfunction Drugs Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Sexual Dysfunction Drugs Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Sexual Dysfunction Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Sexual Dysfunction Drugs Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Sexual Dysfunction Drugs Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Sexual Dysfunction Drugs Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
  49. 8.9 Vietstar Biomedical Research
  50. 8.9.1 Vietstar Biomedical Research Company Information
  51. 8.9.2 Vietstar Biomedical Research Business Overview
  52. 8.9.3 Vietstar Biomedical Research Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Vietstar Biomedical Research Sexual Dysfunction Drugs Product Portfolio
  54. 8.9.5 Vietstar Biomedical Research Recent Developments
  55. 8.10 S1 Biopharma
  56. 8.10.1 S1 Biopharma Company Information
  57. 8.10.2 S1 Biopharma Business Overview
  58. 8.10.3 S1 Biopharma Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 S1 Biopharma Sexual Dysfunction Drugs Product Portfolio
  60. 8.10.5 S1 Biopharma Recent Developments
  61. 8.11 NexMed
  62. 8.11.1 NexMed Company Information
  63. 8.11.2 NexMed Business Overview
  64. 8.11.3 NexMed Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 NexMed Sexual Dysfunction Drugs Product Portfolio
  66. 8.11.5 NexMed Recent Developments
  67. 8.12 Leadiant Biosciences
  68. 8.12.1 Leadiant Biosciences Company Information
  69. 8.12.2 Leadiant Biosciences Business Overview
  70. 8.12.3 Leadiant Biosciences Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Leadiant Biosciences Sexual Dysfunction Drugs Product Portfolio
  72. 8.12.5 Leadiant Biosciences Recent Developments
  73. 8.13 Ivix LLX
  74. 8.13.1 Ivix LLX Company Information
  75. 8.13.2 Ivix LLX Business Overview
  76. 8.13.3 Ivix LLX Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ivix LLX Sexual Dysfunction Drugs Product Portfolio
  78. 8.13.5 Ivix LLX Recent Developments
  79. 8.14 Emotional Brain
  80. 8.14.1 Emotional Brain Company Information
  81. 8.14.2 Emotional Brain Business Overview
  82. 8.14.3 Emotional Brain Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Emotional Brain Sexual Dysfunction Drugs Product Portfolio
  84. 8.14.5 Emotional Brain Recent Developments
  85. 8.15 Apricus Biosciences
  86. 8.15.1 Apricus Biosciences Company Information
  87. 8.15.2 Apricus Biosciences Business Overview
  88. 8.15.3 Apricus Biosciences Sexual Dysfunction Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Apricus Biosciences Sexual Dysfunction Drugs Product Portfolio
  90. 8.15.5 Apricus Biosciences Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Sexual Dysfunction Drugs Value Chain Analysis
  2. 9.1.1 Sexual Dysfunction Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Sexual Dysfunction Drugs Sales Mode & Process
  6. 9.2 Sexual Dysfunction Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Sexual Dysfunction Drugs Distributors
  9. 9.2.3 Sexual Dysfunction Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst